Key Secondary Endpoint: 1,2
- Change from baseline at 18 months vs placebo in Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN)
- Norfolk QoL-DN score is a patient-reported assessment that evaluates neuropathy in domains such as physical function, activities of daily living, symptoms, and autonomic neuropathy (score range -4 to 136)
Change in Norfolk QoL-DN score1,a-c
aNorfolk QoL-DN scores at baseline were 59.6 with ONPATTRO and 55.5 with placebo.1 bBars represent SEM. cN=number of evaluable patients. d95% CI: -19.8, -10.2.1 e95% CI: -27.2, -15.0.1
CI=confidence interval; LS=least squares; SEM=standard error of the mean.
Improvement in quality of life from baseline at 18 months3,f,g
Improvement in quality of life from baseline3,f,g
From New England Journal of Medicine, Adams D, Gonzalez-Duarte A, O’Riordan WD, et al, "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis," 379(1). Copyright © 2018 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
fOdds ratio: 10.0 (4.4-22.5).3
gPercentages based on mITT population: ONPATTRO (n=148); placebo (n=77).1
h95% CI: 43, 59.3
i95% CI: 4, 17.3
More than half of patients treated with ONPATTROexperienced improvement in quality of life3
ONPATTRO demonstrated significant improvement in quality of life as measured by physical, functional, and social assessments.1,4